Opinion|Videos|February 7, 2025
Navigating CLL Treatment Choices
Panelists discuss the factors considered when selecting between BTK inhibitors and venetoclax plus obinutuzumab for chronic lymphocytic leukemia (CLL), the considerations for choosing among acalabrutinib, zanubrutinib, and ibrutinib, and the role of cytotoxic chemotherapy in the treatment of CLL in the era of targeted therapies.
Advertisement
Episodes in this series
- What factors do you consider when selecting between BTK inhibitors and venetoclax plus obinutuzumab for CLL?
- If selecting a BTK inhibitor, what factors do you consider when selecting among acalabrutinib, zanubrutinib, and ibrutinib?
- With the availability of targeted therapies, what role does cytotoxic chemotherapy play in the treatment of CLL?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
ATTR-CM Incidence, Prevalence Rose Sharply in the US
2
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
3
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
4
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
5